参考文献

［1］GARRAN C，CIERVIDE R，CAMBEIRO M，et al.Relationship between day O dosimeters and biochemical relapse-free survival in patients treated with transperineal permanent prostate interstitial brachytherapy with 125I seeds.Brachytherapy，2010，9（1）：8-14.

［2］RIVARD M J，MELHUS C S，SIOSHANSI S，et al.The impact of prescription depth，dose rate，plaque size，and source loading on the central axis using 103Pd，125I and 131Cs.Brachytherapy，2008，7（4）：327-335.

［3］PIGNOL J，RAKOVITCH E，KELLER B，et al.Final tolerance and acceptance results of a phaseⅠ/Ⅱclinical trial of permanent breast 103Pd seed implant.Brachytherapy，2008，7（2）：111-121.

［4］ADKISON J B，THOMADSEN B，HOWARD S P.Systemic iodine-125 activity after Glia Site brachytherapy：Safety considerations.Brachytherapy，2008，7（1）：43-46.

［5］REVARD M J，BULTER W M，DEVLIN W M，et al.American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.Brachytherapy，2007，6（1）：34-37.

［6］POTTERS L，CALUGARU E，JASSAL A，et al.Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy.Int J Radiat Oncol Biol Phys，2006，65（4）：1014-1019.